People
Saccomano Named to OnKure Therapeutics to its Board of Directors
18 January 2022 - - US-based clinical-stage biopharmaceutical company OnKure, Inc has appointed Nicholas A. Saccomano, Ph.D., to its board of directors, the company said.

Dr. Saccomano is a seasoned biopharmaceutical professional with nearly 35 years of research and development experience across multiple therapeutic areas, including oncology.

Previously, Dr. Saccomano worked at Pfizer (NYSE: PFE) R and D, Inc. as chief science officer and Site Head at its Boulder facility, where he led a 170-person research and development team that advanced a portfolio of small molecule drug programs from inception to proof-of-concept.

Prior to working at Pfizer, Dr. Saccomano served as chief science officer at Array Biopharma Inc., where he was responsible for creating and advancing ten clinical-stage compounds, with seven drug approvals to date.

Dr. Saccomano also served as chief technology officer at SomaLogic Inc., where he managed scientific and technical teams in charge of advancing elements of the company's proteomic platform.

He currently serves as a scientific advisor to several innovative life sciences companies. Dr. Saccomano received a B.S. from the State University of New York at Buffalo and a Ph.D. in Organic Chemistry from Columbia University under the direction of Gilbert Stork.

OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer.

Using its proven structure-based drug design approach, the company is building a robust pipeline of tumor-agnostic candidates that are designed to achieve optimal tolerability and efficacy.

OnKure is currently developing its lead clinical candidate, OKI-179, an oral, selective Class 1 HDAC inhibitor, for the treatment of both hematological and solid tumors, with plans to initiate a Phase 2 combination trial with binimetinib in NRAS melanoma in 2022.
Login
Username:

Password: